[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 董阳阳,王建六.子宫内膜癌与代谢综合征的关系及内分泌治疗[J].实用妇产科杂志,2020,36:6.
[3] HOTAMISLIGIL G S.Inflammation and metabolic disorders[J].Nature,2006,444:860-867.
[4] MARTINELLI N,MICAGLIO R,CONSOLI L,et al.Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease[J].Experimental Diabetes Research,2012,2012:1-9.
[5] AVGERINOS K I,SPYROU N,MANTZOROS C S,et al.Obesity and cancer risk:emerging biological mechanisms and perspectives[J].Metabolism,2019,92:121-135.
[6] CHISTIAKOV D A,MELNICHENKO A A,OREKHOV A N,et al.Paraoxonase and atherosclerosis-related cardiovascular diseases[J].Biochimie,2017,132:19-27.
[7] FURLONG C E,MARSILLACH J,JARVIK G P,et al.Paraoxonases-1,-2 and-3:what are their functions?[J].Chem Biol Interact,2016,25(259):51-62.
[8] KORKMAZ H,TABUR S,ÖZKAYA M,et al.Paraoxonase and arylesterase activities in patients with papillary thyroid cancer[J].Scand J Clin Lab Invest,2015,75(3):259-264.
[9] ELKIRAN E T,MAR N,AYGEN B,et al.Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population[J].BMC Cancer,2007,7(1):1-8.
[10] BALCI H,GENC H,PAPILA C,et al.Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung,breast,and colorectal cancer[J].J Clin Lab Anal,2012,26(3):155-160.
[11] SEHITOGULLARI A,ASLAN M,SAYIR F,et al.Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma[J].Redox Rep,2014,19(5):199-205.
[12] UTANĞAÇ M M,YENI E,SAVAŞ M,et al.Paraoxonase and arylesterase activity in bladder cancer[J].Turk J Urol,2017,43(2):147-151.
[13] 封旭,蔡云朗,沈杨.雌激素受体亚型对妇科疾病影响的研究进展[J].东南大学学报(医学版),2013,32(5):651-654.
[14] YUNUSOVA N V,KONDAKOVA I V,KOLOMIETS L A,et al.Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors)[J].Asia Pac J Clin-oncol,2018,14(3):134-140.
[15] KITSON S J,LINDSAY J,SIVALINGAM V N,et al.High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer[J].Gynecol Oncol Rep,2018,23(26):109-110.
[16] KOKTS-PORIETIS R L,MCNEIL J,NELSON G,et al.Prospective cohort study of metabolic syndrome and endometrial cancer survival[J].Gynecol Oncol,2020,158(3):727-733.
[17] YUNUSOVA N V,SPIRINA L V,FROLOVA A E,et al.As-sociation of IGFBP-6 expression with metabolic syndrome and adiponectin and IGF-IR receptor levels in colorectal cancer[J].Asian Pac J Cancer Prev,2016,17(8):3963-3969.
[18] ARTHUR R S,KABAT G C,KIM M Y,et al.Metabolic syndrome and risk of endometrial cancer in postmenopausal women:a prospective study[J].Cancer Causes Control,2019,30(4):355-363.
[19] LINDEMANN K,VATTEN L J,ELLSTRØM-ENGH M,et al.Serum lipids and endometrial cancer risk:results from the HUNT-Ⅱ study[J].Int J Cancer,2009,124(12):2938-2941.
[20] GONG T T,LI D,WU Q J,et al.Cholesterol consumption and risk of endometrial cancer:a systematic review and dose-response meta-analysis of observational studies[J].Oncotarget,2016,7(13):16996-17008.
[21] CHISTIAKOV D A,MELNICHENKO A A,OREKHOV A N,et al.Paraoxonase and atherosclerosis-related cardiovascular diseases[J].Biochimie,2017,132:19-27.
[22] KORKMAZ H,TABUR S,ÖZKAYA M,et al.Paraoxonase and arylesterase activities in patients with papillary thyroid cancer[J].Scand J Clin Lab Invest,2015,75(3):259-264.
[23] CHAI H,HAZAWA M,HOSOKAWA Y,et al.Novel acridine-based N-acyl-homoserine lactone analogs induce endoreduplication in the human oral squamous carcinoma cell line SAS[J].Biol Pharm Bull,2012,35(8):1257-1263.
[24] ARENAS M,GARCÍA-HEREDIA A,CABRÉ N,et al.Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients[J].PLoS One,2017,12(11):e0188633.
[25] SAMRA Z Q,PERVAIZ S,SHAHEEN S,et al.Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients[J].Clin Lab,2011,57(9-10):741-747.
[26] ARIOZ D T,CAMUZCUOGLU H,TOY H,et al.Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer[J].Eur J Gynaecol Oncol,2009,30(6):679-682. |